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Abstract 
Introduction: Pre-operative MRI is being used with increasing frequency to evaluate breast cancer patients, 
but the debate surrounding risks and benefits of this use continues. At our institution, we instituted a 
standardized protocol for pre-operative MRI. Here, we compare patients seen prior to routine use of MRI to 
those seen after and examine effects on surgical choices, timing and outcomes.  
Methods: This is a retrospective review of a prospectively collected database of all new invasive breast 
cancers seen from January 2007 to December 2012. The control group (CG) did not receive MRI, while the 
MRI group (MRG) underwent MRI according to our pretreatment protocol. Groups were compared with 
regards to basic demographics, initial surgical choices, need for re-excision, and surgical timing. The electronic 
medical records of patients in the MRG who underwent mastectomy as their initial surgery were examined 
closely to determine the main factors leading to their choice of surgery. Finally, correlation between findings 
on MRI and final surgical pathology was analyzed. 
Results: Of 282 patients included, 38 were in the CG and 244 in the MRG; the groups were well matched. 
The MRG had a significantly higher percentage of patients choosing initial mastectomy (MRG: 47.1% vs CG 
21.1%, p=0.003). Patients seen in the first 2 years of the study were less likely to choose mastectomy than 
those enrolled in the latter years (29.2%vs 48.6%, p=0.004). The MRG had a lower chance of return to the 
operating room for re-excision (15.2% vs 28.9%, p=0.035). The average time from initial imaging to initial 
surgery was approximately the same between groups (MRG: 39.7 days vs CG 42.1 days, p=0.45) and the MRG 
actually had shorter time to definitive (margin-negative) surgical management (MRG: 43.5 days vs CG: 50.3 
days, p=0.079). One hundred-fifteen patients in the MRG underwent mastectomy as initial surgery. Of these, 
64 (55.7%) had no additional findings on MRI and chose mastectomy based on patient preference; 30 patients 
(26.1%) (29 unilateral, 1 bilateral) had mastectomy because of MRI findings. Of the 31 breasts removed (29 
unilateral and 1 bilateral mastectomies) because of MRI findings, 26 (83.9%) had histologic findings that 
correlated with the MRI findings, while 5 (16.1%) did not.  
Conclusion: Patients receiving routine pre-treatment MRI had an increased mastectomy rate, but had a 
lower re-excision rate. We found no delay to initial surgical therapy and, perhaps more importantly, a slight 
decrease in time to margin-negative surgical therapy in the MRI group. Women choosing mastectomy after 
MRI did so because of personal preference over half of the time, while MRI findings influenced this choice in 
26% of these women. When MRI findings did lead to mastectomy, these findings were confirmed by pathology 
results in the vast majority of cases. 










Over the past two decades, contrast enhanced 
MRI has been integrated into the clinical evaluation of 
breast cancer patients, and its use has increased 
significantly across the United States (1) and Canada 
(2). MRI is accepted as a screening tool in women who 
are at high risk of developing breast cancer based on 
increased sensitivity over mammography. Multiple 
professional societies (NCCN, ACS, ACR) now 
recommend screening MRI for women with a known 
genetic risk factor (BRCA, Cowden Syndrome, etc), 
certain environmental risk factors (radiation to chest 
between age 10 and 30), or an estimated lifetime risk 
of breast cancer of 20% (3-5). The indications for 
pre-treatment MRI in patients carrying a diagnosis of 
breast cancer, however, are much less clear. Current 
NCCN guidelines include a category 2B 
recommendation stating that MRI “may be used” for 
staging prior to operative intervention(6), while the 
American College of Radiology grades the use of MRI 
in intial workup of breast cancer as a 5 on a scale from 
1 to 9, classifying its use as “may be appropriate.” (4) 
The lack of a clear consensus in the current literature 
on this issue contributes directly to the ambiguity of 
these recommendations. 
The promise of MRI in the pre-treatment setting 
is the same as when used for screening, namely 
increased sensitivity. MRI sensitivity in detecting 
multicentric (MC) and contralateral disease has been 
quoted as high as 93% and 88% compared to 46% and 
19%, respectively, for conventional mammogram and 
ultrasound (7). This increased sensitivity seems to be 
particularly valid in patients with dense breasts (8) or 
with lobular cancers (9). In theory, this increase in 
sensitivity should lead to fewer positive margins, 
decreased re-excision rates, and potentially lower 
local recurrence rates if additional clinically relevant 
disease can be detected. The results of studies 
examining these issues, however, have been mixed. 
While increased sensitivity can be a strength, it 
can also be a detriment if not coupled with 
appropriate specificity. MRI has been associated with 
delays in treatment, increased costs (in part due to 
workup of additional findings), and increased 
mastectomy rates. These delays and additional 
mastectomies may be justified if the MRI findings are 
confirmed by pathology findings and serve to reduce 
margin positivity, but this is not always the case. 
Bleicher et al. summarized these concerns well in their 
report. Compared to those without MRI, patients 
undergoing pretreatment MRI had a 22.4-day delay in 
pretreatment evaluation and an odds ratio for 
mastectomy of 1.80; simultaneously, there was no 
decrease in positive margins at lumpectomy, nor a 
decrease in conversion from breast conservation to 
mastectomy (10). Along the same lines, Aranout, et al. 
recently published a report of a population-based 
study of patients in Canada over a 10-year period in 
which they found that pre-treatment MRI was 
associated with increased post-diagnosis imaging and 
biopsies, more contralateral prophylactic 
mastectomies, and a greater than 30-day wait to 
surgery (2). 
These two reports are representative of the 
literature available on this topic, with mainly 
retrospective studies that involve populations where 
MRI was used selectively and infrequently (only 
14.8% of patients across the Aranout study had 
pre-treatment MRI), opening interpretation of any 
data on the subject to significant bias. Also, the 
inconsistent, non-standardized use of MRI fails to 
streamline the process, and could even adversely 
affect the diagnostic accuracy of MRI if interpretation 
is left to providers who are unfamiliar with its use. At 
our institution, we have unique advantages for 
evaluating routine use of pretreatment MRI. First, 
patients receive care as military beneficiaries, and 
pre-operative tests are performed without any need 
for insurance approval. Second, patients receive all of 
their cancer care in one facility, potentially 
streamlining their diagnostic work-up and transitions 
between providers. Finally, we instituted a diagnostic 
protocol in which all patients with biopsy-proven 
invasive breast cancer are scheduled for bilateral 
breast MRI upon pathologic diagnosis. Our 
single-payer, single institution system gives us a 
distinctive opportunity to study how efficiently a 
system can accomplish routine breast MRI and to 
examine the effects of this test on surgical outcomes. 
Barchie et al. reported our early experience with this 
protocol and showed that we had no delay in therapy. 
Furthermore, while mastectomies were increased, 
they found high MRI sensitivity and specificity for 
multifocal (MF)/MC disease (89.5% and 84.2%, 
respectively) (11). In this study, we examine our 
complete experience with standardized use of 
pre-treatment MRI over a 6-year period.  
Methods 
Patient Selection 
This is a retrospective review of a prospectively 
collected database of all new invasive breast cancer 
cases seen at San Antonio Military Medical Center 
(SAMMC) from January 2007 to December 2012. We 
prospectively gathered demographic, diagnostic, 




pathologic and treatment information for all patients 
seen in our Breast Cancer Comprehensive Care 
Conference (BC4) clinic during this time. In 
September 2007, we instituted a protocol of 
standardized preoperative bilateral breast MRI for all 
biopsy-proven invasive cancers. The protocol was 
approved and monitored by the SAMMC Institutional 
Review Board. Patients who did not receive MRI, 
most of whom were evaluated from January 2007 to 
September of 2007, constituted a control group (CG), 
while patients seen after this date who received MRI 
were considered the MRI group (MRG). The SAMMC 
IRB waived the requirement for informed consent 
prior to MRI. Patients were excluded if they were 
treated with neo-adjuvant therapy, refused surgery, 
had metastatic disease, had incomplete data, or were 
lost to follow-up (Figure 1, consort diagram). 
Treatment Protocol 
The pretreatment MRI protocol was 
administered exclusively at SAMMC to Tricare 
beneficiaries. All patients with mammographic 
abnormalities underwent image-guided biopsy. 
Patients with biopsy proven invasive carcinoma were 
placed into the institutionally supported imaging 
pathway. A renal function panel was obtained and the 
patient was scheduled for MRI at their earliest 
convenience. On occasion, patients with BIRADS 5 
lesions underwent MRI prior to biopsy at the 
discretion of the attending radiologist. The patient 
then underwent MRI, with the goal of finalized 
interpretation prior to the patient’s appointment in 
the multi-disciplinary BC4 clinic. Here, each patient 
was seen by a surgeon, a radiation oncologist and a 
medical oncologist. Providers then met, generally that 
same afternoon, in a multi-disciplinary conference, 
which included providers from General 
Surgery/Surgical Oncology, Radiation Oncology, 
Diagnostic Radiology, Medical Oncology, Pathology, 
as well as a Breast Care Nurse. 
MRI Technique 
MRI was conducted with 1.5 Tesla Marconi and 
Siemens Esprit magnets with InVivo dedicated seven 
channel breast coils. Core sequences include axial 
STIR, 3D axial T1, T2 sagittal fat saturated, pre and 
post dynamic contrast axial T1 SPGR fat saturated 
images with and without subtraction. Post-contrast 
images were repeated to 5min with 60 sec temporal 
resolution. Slice thickness was 0.9mm with 0.89mm 
in-plane resolution. Matrix size was 381 x 448 with 
field of view of 34 x 30 cm. Coronal and sagittal 
reformats were obtained. All studies were performed 
at SAMMC and interpreted by board certified staff 
radiologists. The MRI was scheduled at the earliest 
possible time, regardless of menstrual cycle, to avoid 
delay of definitive management, accepting possible 
negative impact on sensitivity and specificity (12). 
Contrast administration was automated with a 
0.1mmol/kg gadolinium injection followed by a 10mL 
flush.  
Data Collection and Analysis 
The breast cancer database was reviewed for 
basic demographic data, histological diagnosis, 
surgical interventions, and temporal relationships 
between imaging, biopsy and surgery dates. Clinical 
stage was determined by initial surgical specimen. 
Time from initial radiologic detection to final 
(margin-negative) surgical management was recorded 
in order to analyze any delay in surgical treatment. 
The records of patients undergoing mastectomy after 
MRI were reviewed very closely to determine the 
reason for their choice of mastectomy. Pre-operative 
clinic notes were examined for the discussion between 
patient and surgeon/oncologist and, when possible, a 
reason for mastectomy was assigned based on these 
notes. Final pathology reports from these cases were 




Figure 1. Consort Diagram 




Fisher’s exact test was used to investigate if 
proportional differences existed between the MRG 
and the CG with regards to histological subtype, 
stage, mastectomy rate, re-excision rate, and rate of 
conversion from BCT to mastectomy. The Student t 
test was used for statistical analysis of continuous 
variables. Mann-Whitney U test was used for 
comparison of independent, nonparametric variables, 




A total of 370 patients with invasive breast 
cancer were seen in BC4 clinic between January 2007 
and December 2012. Of those patients, 88 patients 
were excluded: 48 underwent neoadjuant therapy, 25 
were lost to follow-up, 10 had incomplete data 
available, 4 had metastatic disease and 1 refused 
surgery (Figure 1). Of the remaining 282 patients, 38 
(13.5%) did not receive a pre-treatment MRI, most 
being seen immediately prior to institution of the MRI 
protocol, and made up the control group (CG). The 
other 244 patients (86.5%) received pre-treatment MRI 
per protocol and, thus, were the MRI group (MRG). 
The MRG and CG were very well matched with 
respect to age, tumor size, histology, tumor grade, 
nodal status, ER positivity, HER2 positivity, and triple 
negative disease (p>0.05) (Table 1). 
 
Table 1. Demographics 
  MRI CG p value 
Age 58.60 59.10 0.78 
Size (cm) 1.79 1.56 0.34 
Ductal Histology 85.0% 86.5% 0.81 
High Grade 20.0% 16.2% 0.59 
Node Pos 30.0% 28.6% 0.86 
ER- 14.6% 18.2% 0.59 
HER2+ 12.8% 3.0% 0.10 
Triple Neg 9.4% 15.2% 0.30 
 
Initial Surgical Procedure 
Overall, 159 (56.4%) patients chose BCT, while 
123 (43.6%) patients chose mastectomy as initial 
procedure. The MRG had a significantly higher 
percentage of patients choosing mastectomy as their 
initial procedure compared to the CG (47.1% vs 21.1%, 
p=0.003). The rate of mastectomy as initial procedure 
changed over time. Regardless of group, patients seen 
in the first 2 years of the study (2007-2008, n=72) were 
less likely to choose mastectomy than those enrolled 
in the latter years (2009-2012, n=209) (29.2%vs 48.6%, 
p=0.004). Limiting analysis to the MRG, patients prior 
to 2009 were also less likely to choose mastectomy 
compared to those seen in 2009 and afterwards, 
thought this difference lost significance (36.6% vs 
49.3%, p=0.14).  
Within the MRG, mastectomy patients had more 
advanced and high-risk disease than those choosing 
BCT. While MRG mastectomy and BCT patients were 
similar in age, grade, ER status, and percentage with 
triple negative disease, MRG mastectomy patients 
had significantly larger tumors (p<0.01), more HER2+ 
disease (p=0.01), and more node positive disease 
(p=0.05) (Table 2).  
 
Table 2. MRG Demographics 
  BCT Mastectomy p value 
Age 59.6 57.7 0.20 
Size 1.44 2.15 <0.01 
Ductal Histology 90.2% 79.5% 0.02 
High Grade 17.9% 22.2% 0.40 
Node Pos 24.4% 35.9% 0.05 
ER- 13.0% 16.2% 0.48 
HER2+ 7.5% 18.4% 0.01 
Triple Neg 9.1% 9.6% 0.88 
 
Re-excision Rate 
Though there was a clear increase in mastectomy 
as initial surgical choice within the MRG, this group 
also had a lower chance of return to the operating 
room for re-excision (15.2% vs 28.9%, p=0.035). 
Limiting analysis to patients who initially chose BCT, 
the MRG still had a lower rate of re-excision, though 
not significantly (28.7 vs 36.7%, p=0.39).  
Surgical Timing 
We examined the average time for each group to 
get from initial imaging with suspicious findings to 
surgical management. From imaging to initial 
surgery, the two groups averaged roughly the same 
interval (MRG: 39.7 days vs CG 42.1 days, p=0.45). We 
next examined surgical timing of the two groups in 
reference to a potentially more meaningful time point, 
time from initial imaging to definitive 
(margin-negative) surgical management. The MRG 
actually reached this endpoint on average one week 
faster than the CG, with a trend toward statistical 
significance (MRG: 43.5 days vs CG: 50.3 days, 
p=0.079).  
MRI Patients Choosing Mastectomy 
 There were 115 patients in the MRG who 
underwent mastectomy as initial surgery; these 
patients were closely reviewed to determine the 
reason for mastectomy. The results of this analysis are 
demonstrated in Figure 2. The reason for mastectomy 
could not be clearly determined in 3 (2.6%) patients. 
Seventeen (14.8%) patients had a contraindication to 




BCT prior to MRI (12 with MC disease on 
mammogram or ultrasound, 4 with a history of prior 
radiation, and 1 with inflammatory breast cancer), so 
their decision was not affected by MRI results. One 
patient was found to be BRCA positive prior to 
surgery and elected to undergo bilateral mastectomy 
as a result. Thirty patients (26.1%) had mastectomy 
because of an MRI finding (1 patient with tumor 
>5cm, 1 with chest wall involvement, 4 with MF 
disease and 24 with MC disease). Sixty-four (55.7%) 
patients had no additional findings on MRI and 
instead had mastectomy based on patient preference. 
Bilateral Mastectomy 
A total of twelve patients in the MRG had 
bilateral mastectomies, 2 because of imaging findings 
and 10 for prophylaxis. Of the 2 patients with imaging 
findings, 1 patient had findings of bilateral disease on 
mammogram (MRI did showed a corresponding 
finding), with corresponding pathology results. The 
other patient had no mammographic evidence of 
disease on the contralateral side, but MRI showed an 
area of suspicion, which was recommended for 
biopsy. This patient chose to forego second biopsy 
and instead to have bilateral mastectomies. Final 
pathology from the contralateral breast did show 
DCIS in the area that was suspicious on MRI. In the 
remaining 10 patients, contralateral MRI was negative 
and pathology showed no areas of DCIS or invasive 
malignancy. Overall, MRI correctly identified two 
cases of contralateral disease, one of which was not 
seen on other imaging modalities. 
MRI/Pathology Correlation 
Of the 31 breasts removed from 30 patients (29 
unilateral, 1 bilateral mastectomies) because of new 
MRI findings, 26 (83.9%) had histologic findings that 
correlated with the MRI results. Conversely, 5 (16.1%) 
had no histologic correlate of MRI findings, 4 of which 
were thought to have MC disease and one thought to 
have MF disease. Overall, of the 244 patients who 
underwent MRI, 30 (12.3%) underwent mastectomy 
because of a positive MRI; 5 patients with false 
positive results and 25 with true positive results. All 5 
patients with false positive MRI findings were offered 
MRI guided biopsy of their additional MRI finding, 
but refused biopsy and instead chose to move 
forward with mastectomy. 
Discussion 
In our retrospective review of this prospectively 
collected data set, we found that after a standardized 
protocol of pre-operative MRI was initiated, patients 
who underwent MRI had a higher mastectomy rate 
than historical controls without MRI, but had less 
need for re-excision. Routine pretreatment MRI was 
not associated with delay in care, with initial surgery 
occurring in approximately the same interval after 
diagnosis, and margin-negative surgery actually 
being accomplished more quickly in patients 
receiving MRI. Importantly, over half of the patients 
in the MRG choosing mastectomy did so because of 
their preference, not because of the MRI findings. 
Additionally, roughly 10% of patient had true positive 
MRIs leading to mastectomy, while only 5 patients 
(2.1%) underwent mastectomy because of false 
positive findings on MRI. 
A number of studies have reported increased 
mastectomy rate when women undergo pre-operative 
MRI, and our results reinforce this finding. While 
there is clearly a correlation between MRI and 
mastectomy, a direct causal relationship is not as 
clear. Our study is based on retrospective analysis and 
a comparison of historical controls to more recently 
evaluated patients. This difference in temporal 
evaluation of patients makes the observed difference 
difficult to interpret as mastectomy rates across the 
United States have been increasing over the last 10 
 
Figure 2. MRG Patients chosing mastectomy 
 




years. A recent report of NSQIP data from 2005-2011 
showed a relative increase in mastectomy of 2.9% per 
year during that time (13). Additionally, the SEER 
database showed the mastectomy rate in 2011 was 
46% (14), which is roughly the same as the 
mastectomy rate in the MRG. Meanwhile, our control 
group mastectomy rate of 17.9% was quite low 
compared to the national average at that time 
(roughly 40%) (13). Furthermore, even within our 
own study, there was an increase in the mastectomy 
rate comparing patients from the first 2 years to later 
patients. This difference may be in part due to the 
MRG all being treated later in the trial, but even 
within the MRG, an increase in mastectomy in the 
latter portion of the trial was observed, though this 
difference was not as large.  
The relationship between MRI and mastectomy 
is indeed complicated, as the social acceptance of 
mastectomy has evolved during the same time period 
in which MRI use has increased, making it difficult to 
identify the causative factor. Aranaout et al. found an 
increase in mastectomy associated with MRI use, but 
the use of MRI increased from 3% at the beginning of 
their study (2003) to 24% at the end (2012), during 
roughly the same time that Lucas, et al. showed an 
increase in mastectomy rates independent of any 
specific imaging (2, 13). Given the complicated nature 
of literature on this issue, we closely reviewed charts 
of MRG patients choosing mastectomy to discern the 
reasons for this choice. We found that over half of the 
patients choosing mastectomy after MRI did so 
because of choice, despite having negative MRIs. Only 
26% of women choosing mastectomy in the MRG did 
so because of MRI findings. Indeed, the increase in 
MRI use over the past decade has coincided with, but 
did not necessarily cause, the trend of increased 
mastectomy during the same time. Ultimately, the use 
MRI in our study, similar to multiple others, is 
correlated with increased mastectomy, but was not 
the only cause of this increase.  
While a certain percent of mastectomies may be 
explained by population trends, we were able to 
identify a population of patients whose decision was 
directly attributed to MRI findings. As noted above, 
the decision to undergo initial mastectomy was 
affected by MRI findings in roughly 12.3% of patients 
undergoing MRI. Of these patients, pathology results 
confirmed that the vast majority (83.9%) of these 
findings correlated with DCIS or invasive cancer, 
which likely would have likely necessitated a second 
trip to the operating room for re-excision. This result 
confirms the early findings reported by Barchie et al. 
on the use of routine pretreatment MRI, which 
showed a high specificity for MC and MF disease (11). 
Additionally, we did identified a decreased 
re-excision rate in the MRG, implying that, for some, 
the increased sensitivity of MRI did have clinical 
benefit and, potentially, some of the mastectomies in 
the MRG may have been justified. What we cannot 
determine from our data set is whether these 
additional findings would have affected long-term 
oncologic outcomes. Randomized, prospective data 
are needed to determine the ultimate meaning of this 
increase in mastectomy that we, and others, have 
noted. Importantly, the five patients with false 
positive MRIs were offered MRI-guided biopsy, but 
refused. In order to avoid similar unnecessary 
mastectomies, patients who do undergo 
pre-treatment MRI should be counseled regarding the 
known possibility of false-positive findings and the 
need for biopsy of additional findings.  
The other major criticism of pretreatment MRI 
has been delays in definitive surgical management. As 
noted earlier, Bleicher et al. found a 22.4-day delay in 
pretreatment evaluation for patients receiving MRI 
(10). These delays are attributed to the process of 
carrying out the test (need for approval, the time 
needed to schedule and actually complete the test), as 
well as the additional findings of MRI (the time 
needed to work up any new findings with additional 
imaging and/or biopsies). In our trial, however, we 
found no increase in time to surgery for the MRG. 
This finding, which is in stark contrast to most 
contemporary data, is likely in part attributed to 
ubiquitous and protocolized use of “in-house” MRI, 
which streamlines the process. Additionally, the 
ability to complete the MRI and any further work-up 
within a single institution decreases delays associated 
with scheduling and completing tests at multiple 
facilities. While this may not be applicable to all health 
systems, our data show that it is possible to obtain 
pre-operative MRI without significant delay. 
In addition to time to initial surgery, we 
examined a potentially more clinically meaningful 
end-point, time to margin-negative resection. Likely 
due to a decreased re-excision rate in the MRG, we 
found that pretreatment MRI actually led to a trend 
towards decreased time to margin-negative resection. 
Ultimately, rather than basing merit of a pre-operative 
test on how quickly a patient undergoes an initial 
operation, a better metric might be time to completion 
of surgical treatment (to include reoperation for 
positive margins). This outcome better correlates with 
the start of recovery from surgery, start of adjuvant 
therapies, and, importantly, return to regular life 
without the stress of waiting for the result of another 
pathologic assessment. We suggest that time to 
margin-negative surgery, rather than time to initial 
surgery, is a more meaningful end-point for the 
evaluation of a pre-operative imaging modality.  




While our results are interesting, our institution 
is somewhat unique. We have a single, large medical 
center where the majority of our patients receive all of 
their care, to include all imaging and image-guided 
biopsies. Also, almost all of our patients fall within a 
single payer system, with no debate regarding 
insurance coverage of diagnostic tests that are not 
currently standard-of-care. Perhaps most importantly, 
we have instituted a standardized protocol of 
pre-operative MRI. Our results indicate that these 
factors allow for the completion of pre-operative MRI 
without any delay in care. While this may not 
translate to every health care system, it offers a 
glimpse of what is possible and indicates that if such a 
system can be instituted, concern for delaying a 
patient’s care should not dissuade clinicians from the 
use of MRI. 
There are several limitations to this study. First, 
this is a retrospective review with a non-randomized 
and non-contemporary control group. This introduces 
a number of issues, particularly because the rate of 
mastectomy has increased nationwide during the time 
of our study. Additionally, our control group is rather 
small, opening it to additional bias, such as the low 
number of women choosing mastectomy in the CG, as 
discussed above. Finally, our patient register is not set 
up to maintain lengthy follow-up records and, thus, 
we do not have long-term outcomes data on our 
patients. One of the true tests for pre-treatment MRI 
will be whether the increased sensitivity and change 
in surgical approach will affect oncologic outcomes. 
Specifically, will a decrease in positive margins with 
pre-operative MRI lead to a decrease in the local 
recurrence rate and, potentially, a decrease in 
disease-specific mortality? Unfortunately, our data 
does not allow us to comment on this potential 
outcome. 
Conclusion 
In conclusion, we have performed a 
retrospective review of our prospectively gathered 
database of breast cancer patients at our institution. 
We instituted a protocol to accomplish routine 
pre-treatment MRI for all women with a diagnosis of 
invasive breast cancer and compared patients who 
underwent pretreatment MRI to those who did not. 
Patients receiving MRI did have increased 
mastectomy rates as expected from previous reports, 
but had a lower re-excision rate. We found no delay to 
initial surgical therapy and perhaps more 
importantly, a slight decrease in time to 
margin-negative surgical therapy in the MRG. 
Women choosing mastectomy after MRI did so 
because of personal preference (and despite negative 
MRI findings) over half of the time, while MRI 
findings influenced this choice in 26% of these 
women. When MRI findings did lead to mastectomy, 
these findings were confirmed on histology in the vast 
majority of cases. Future studies will be focused on 
applying this protocol in non-invasive disease and 
comparing our invasive patients to those of other 
similar military hospitals, where pre-treatment MRI is 
used more sparingly to assess oncologic outcomes. 
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